drugset
drugset / Trial / NCT05827653

MAD Study of NX210c

NCT05827653 ↗

Phase 1 Completed 29 enrolled Axoltis Pharma Centre for Human Drug Research, Netherlands · collab
RandomizedParallel-groupDouble-blindBasic science

Summary

This study will investigate the safety and tolerability of multiple intravenous infusions of NX210c with two ascending doses as well as NX210c pharmacokinetics (PK), and pharmacodynamics (PD) effects in healthy elderly subjects.

Timeline

Start
2022-12-05
Primary completion
2023-04-29
Completion
2023-10-02

Drugs

EvaluationDrugModalityDoseRoute
Subject NX210c Unknown — Intravenous

Indications

No indication recorded.